ATE216892T1 - Inhibitor von nebenwirkungen zur krebstherapy - Google Patents

Inhibitor von nebenwirkungen zur krebstherapy

Info

Publication number
ATE216892T1
ATE216892T1 AT92923166T AT92923166T ATE216892T1 AT E216892 T1 ATE216892 T1 AT E216892T1 AT 92923166 T AT92923166 T AT 92923166T AT 92923166 T AT92923166 T AT 92923166T AT E216892 T1 ATE216892 T1 AT E216892T1
Authority
AT
Austria
Prior art keywords
cancer therapy
side effects
inhibitor
hgf
effect
Prior art date
Application number
AT92923166T
Other languages
English (en)
Inventor
Toshikazu Nakamura
Original Assignee
Toshikazu Nakamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toshikazu Nakamura filed Critical Toshikazu Nakamura
Application granted granted Critical
Publication of ATE216892T1 publication Critical patent/ATE216892T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92923166T 1991-11-07 1992-11-05 Inhibitor von nebenwirkungen zur krebstherapy ATE216892T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32141291A JP3394982B2 (ja) 1991-11-07 1991-11-07 ガン療法用副作用防止剤
PCT/JP1992/001433 WO1993008821A1 (fr) 1991-11-07 1992-11-05 Inhibiteur des effets secondaires dans la therapie du cancer

Publications (1)

Publication Number Publication Date
ATE216892T1 true ATE216892T1 (de) 2002-05-15

Family

ID=18132263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92923166T ATE216892T1 (de) 1991-11-07 1992-11-05 Inhibitor von nebenwirkungen zur krebstherapy

Country Status (5)

Country Link
EP (1) EP0724884B1 (de)
JP (1) JP3394982B2 (de)
AT (1) ATE216892T1 (de)
DE (1) DE69232596T2 (de)
WO (1) WO1993008821A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2144081C (en) * 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
AU1757100A (en) * 1994-03-18 2000-05-11 Toshikazu Nakamura Drug for relieving side effects caused by immunosuppressants
JP3962097B2 (ja) * 1994-03-18 2007-08-22 敏一 中村 免疫抑制剤による副作用の軽減剤
WO1996032960A1 (fr) * 1995-04-21 1996-10-24 Mitsubishi Chemical Corporation Medicament preventif ou therapeutique, ou les deux, pour les affections ischemiques
CA2230819C (en) 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
US5855918A (en) * 1995-09-12 1999-01-05 Genentech, Inc. Cystic fibrosis therapy
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
CN1222310C (zh) * 1998-08-05 2005-10-12 住友制药株式会社 肝实质细胞增殖因子药用制剂
EP1320384B1 (de) 2000-08-28 2007-10-10 Damavand Wound AB Die synergistischen wirkungen von hgf und antibakterieller behandlung
JP4716875B2 (ja) 2003-12-16 2011-07-06 敏一 中村 糖鎖欠損型肝細胞増殖因子
JP5093783B2 (ja) 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
KR20200144576A (ko) * 2018-05-17 2020-12-29 주식회사 헬릭스미스 화학요법-유발 말초신경병증과 관련된 신경병증성 통증의 치료

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045534A (ja) * 1983-08-22 1985-03-12 Otsuka Pharmaceut Co Ltd 肝実質細胞増殖因子
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
JPH01143900A (ja) * 1987-11-30 1989-06-06 Terumo Corp 肝修復因子
JP2799455B2 (ja) * 1988-11-15 1998-09-17 工業技術院長 肝実質細胞増殖因子の製造法
JPH03130091A (ja) * 1989-06-05 1991-06-03 Toyobo Co Ltd 組換ヒト肝実質細胞増殖因子
JP2577091B2 (ja) * 1989-08-11 1997-01-29 三菱化学株式会社 肝実質細胞増殖因子及びそれをコードする遺伝子
JPH03204899A (ja) * 1989-09-21 1991-09-06 Otsuka Pharmaceut Co Ltd ヒト肝再生因子、そのｄｎａ塩基配列、該配列を含むプラスミド及び形質転換体並びにリコンビナント肝再生因子

Also Published As

Publication number Publication date
DE69232596T2 (de) 2003-01-09
JP3394982B2 (ja) 2003-04-07
EP0724884A4 (de) 1995-11-14
EP0724884B1 (de) 2002-05-02
EP0724884A1 (de) 1996-08-07
DE69232596D1 (de) 2002-06-06
JPH06340546A (ja) 1994-12-13
WO1993008821A1 (fr) 1993-05-13

Similar Documents

Publication Publication Date Title
DE69232596D1 (de) Inhibitor von nebenwirkungen zur krebstherapy
RU94026082A (ru) Применение вортманнина и его аналогов для получения препарата для ингибирования фосфатидилинозитол-3-киназы у млекопитающих и для получения препарата для лечения фосфатидилинозитол-3-киназа-зависимых состояний
DK1316308T3 (da) Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
MX9206577A (es) COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
GEP20012500B (en) Inhibitors of Protein Farnesyl Transferase
IL81887A0 (en) Dihydroisoxazole derivatives,their preparation and pharmaceutical compositions containing them
DK0668769T3 (da) Egebarkekstrakt-relaterede syntetiske sammensætninger og fremgangsmåde til deres anvendelse
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
DE69202441D1 (de) Melatoninderivate und Kombinationen mit Antiestrogenen zur Behandlung von Brustkarzinoma.
ZA981609B (en) Method of treating a tumor
DE3685484D1 (de)
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
ATE262330T1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
CA2078544A1 (en) Method and compositions for treating injury
KR890000108A (ko) 종양 치료용 약제학적 조성물
DE69218200D1 (de) Behandlung von leberkrebs
ATE227991T1 (de) Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
MX9202156A (es) Novedosos compuestos para reducir el colesterol.
DE3485282D1 (de) Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
MY105075A (en) Cancer treatment
MX9606137A (es) Composiciones y metodos para el tratamiento de tumores.
RU96122672A (ru) Эхинамакс. способ лечения астенических состояний при физиогенных дезадаптациях

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties